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ABSTRACT Each year, millions of African children receive praziquantel (PZQ) by mass drug administration (MDA) to treat
schistosomiasis at a standard single dose of 40 mg/kg of body weight, a direct extrapolation from studies of adults. A higher dose
of 60 mg/kg is also acceptable for refractory cases. We conducted the first PZQ pharmacokinetic (PK) and pharmacodynamic
(PD) study in young children comparing dosing. Sixty Ugandan children aged 3 to 8 years old with egg patent Schistosoma man-
soni received PZQ at either 40 mg/kg or 60 mg/kg. PK parameters of PZQ racemate and enantiomers (R and S) were quantified.
PD outcomes were assessed by standard fecal egg counts and novel schistosome-specific serum (circulating anodic antigen
[CAA]) and urine (circulating cathodic antigen [CCA]) antigen assays. Population PK and PD analyses were performed to esti-
mate drug exposure in individual children, and the relationship between drug exposure and parasitological cure was estimated
using logistic regression. Monte Carlo simulations were performed to identify better, future dosing regimens. There was marked
PK variability between children, but the area under the concentration-time curve (AUC) of PZQwas strongly predictive of the
parasitological cure rate (CR). Although no child achieved antigenic cure, which is suggestive of an important residual adult
worm burden, higher AUCwas associated with greater CAA antigenic decline at 24 days. To optimize the performance of PZQ,
analysis of our simulations suggest that higher doses (>60 mg/kg) are needed, particularly in smaller children.
IMPORTANCE Schistosomiasis is a neglected tropical disease, typically associated with chronic morbidity, and its control is a
global health priority. Praziquantel (PZQ) is the only available antiparasitic drug and is often given out, as a single oral dose
(40 mg/kg), to school-aged children by mass drug administration (MDA) schemes operating within preventive chemotherapy
campaigns as endorsed by theWorld Health Organization (WHO). This current strategy has several limitations. (i) It excludes
preschool children who can be patently infected. (ii) It delivers PZQ at a dose directly extrapolated from adult pharmacological
studies. To address these problems, we conducted the first pharmacokinetic and pharmacodynamic study of young children
within an area of Uganda where Schistosoma mansoni is hyperendemic. Our results demonstrate that a higher dose (>60 mg/kg)
is required, especially in smaller children, and draw attention to the need for further optimization of PZQ treatment based on
schistosome antigenic assays, which are more sensitive to pharmacodynamic markers.
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Schistosomiasis is an important waterborne parasitic disease.An estimated 779 million people are at risk, and more than
50% of those are children (1, 2). Adult female schistosomes shed
copious numbers of eggs each day that are either eliminated in
host excreta or become lodged within host tissues. Chronic schis-
tosomiasis is caused by the gradual accumulation of fibrotic le-
sions that occur around trapped eggs (2). To avert present and
future morbidity, preventive chemotherapy campaigns, as en-
dorsed by theWorld Health Organization (WHO), offer praziqu-
antel (PZQ) via mass drug administration programs (MDA) to
school-aged children.
PZQ is a pyrazinoisoquinoline drug licensed for oral use in
children aged 4 years and above (3) and the only available treat-
ment for the three principal Schistosoma species that cause human
disease, Schistosoma haematobium, S. mansoni, and S. japonicum.
The drug’s biovailability is enhanced by concomitant food admin-
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istration (4), and it undergoes an extensive first-pass metabolism
in the liver by the cytochrome P450 (CYP) system (CYP1A2,
CYP3A4, CYP2BI, CYP3AD, and CYPC19) (5). PZQ is usually
administered as a single dose between 40 and 60 mg/kg of body
weight (6). PZQ damages the adult worm tegument by disrupting
calcium ion channels—such damage may facilitate subsequent
immunological attack and later clearance of the parasite. How-
ever, immature worms (schistosomulum) are insensitive to PZQ
(1, 7). As adult worm death cannot be measured directly because
of their intravascular location, the pharmacodynamics of PZQ is
currently estimated using fecal egg clearance 3 to 4 weeks after
treatment (8). Alternative biomarkers with potential prognostic
value are measured by newly developed schistosome antigen as-
says using sera or urine (9, 10). Globally, the performance of PZQ
is considered satisfactory, but there are some well-known excep-
tions that occur in some areas where schistosomiasis is hyperen-
demic. It is likely that these deficiencies are caused by insufficient
drug exposure by inadequate initial dosing (11, 12).
Current formulations of PZQ are racemates consisting of two
enantiomers [()R and ()S], previously known as levo (L) and
dextro (D) stereoisomers. A long-held belief is that the R isomer is
significantly more active than the S form against S. japonicum and
S. mansoni, although rodent studies are somewhat contradictory
(13–16). In addition, R-PZQ ismuchmore palatable than S-PZQ,
and a monoenantiomeric formulation, currently in development,
could reduce the dose by half, thus decreasing the total size of
administered tablets (5, 13–18).
Despite being administered to an estimated 25million children
every year (19, 20), there is only limited pharmacokinetic and
pharmacodynamic (PK-PD) information on the enantioselective
properties of PZQ. The currently recommended dose of 40mg/kg
is a direct extrapolation from adults (5). Several epidemiological
studies have revealed persistent egg patent schistosomiasis in
preschool-aged children and in infants (11, 21–23) with poor
worm clearancewhen given a standard dose at 40mg/kg (4, 20, 24,
25). While this evidence has led to a change in WHO guidelines
that now promote access to PZQ in younger children (9, 21, 26),
detailed PK-PD studies are still lacking.We report here on the first
PZQ PK-PD study in children aged 3 to 8 years infected with
S. mansoni.
RESULTS
A total of 60 childrenwere enrolled in the study, and 59 completed
the study protocol. One child was excluded 6 h into the study
because of an acute febrile illness that was later diagnosed and
treated as falciparummalaria (Fig. 1). No child tested positive for
HIV (Table 1).Overall, therewere nomajor clinical adverse events
that were identified. All unpleasant symptoms, mostly sweating,
abdominal pain and cramps, nausea, vomiting, headache, dizzi-
ness, and sleepiness, peaked between 1 and 4 h after receipt of PZQ
and subsided between 1 and 3 h after the onset of symptoms. The
side effects observed by the study pediatrician (ALB) were greater
than the self-reported ones. The most common ones were sweat-
ing, abdominal pain and cramps, sleepiness, and headache. These
symptoms were significantly greater in the 60-mg/kg arm (see
Fig. S1 in the supplemental material). Fifty-eight children were
available at the 24-day follow-up.
PZQ pharmacokinetics. The individual plasma PZQ enantio-
mer concentration-time profiles are shown in Fig. 2. There was
marked pharmacokinetic variability in the concentrations of both
the R and S isoforms. Table 2 shows pharmacokinetic parameter
values at different doses for each enantiomer. This was evident in
both the “spaghetti plot” and in the coefficient of variation (CV)
of the population PK estimates for clearance and volume, which
was60% from both population PKmodels (Table 3). There was
no relationship between any of the Bayesian estimates of the pa-
rameter values and any of the available covariates. Thus, the stan-
dard base model was used. The fit of the model to the data was
satisfactory, although there was a degree of bias when the popula-
tion parameter values were used. The observed-predicted plots
both before and after the Bayesian step are shown in Fig. 3.
PZQ pharmacodynamics. (i) S. mansoni cure rate and egg
rate reduction by fecal examination. Both overall cure rate (CR)
and egg reduction rate (ERR) were used to assess the parasitolog-
ical response to PZQ. There were no statistically significant differ-
ences in the day 24 stool egg detection CR or ERR between the two
doses of PZQ (Table 4). The odds ratios from logistic regression
models of the cure rate are shown in Table 5 There is some evi-
dence for an association of cure rate with gender, weight, and
initial parasite load, but these would not be considered statistically
significant after allowing for the number of parameters tested. As
noted above, there is no significant association between cure and
administered PZQ dose. In contrast, total PZQ AUC0–24 (area
under the concentration-time curve from 0 to 24 h) and in partic-
ular the S form are associated with increased cure rates. The
Akaike information criterion (AIC) measures of goodness-of-fit
provide some positive evidence in favor of the S form, but there
FIG 1 Design and basic methodology of the study. The SIMI cohort refers to
the Schistosomiasis in Mothers and Infant Study.
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was no strong evidence than it necessarily has better explanatory
value than total AUC. Furthermore, it should be noted that the R
form was present in much lower concentrations, and it is possible
that drug exposure (in terms of AUC)was not be accurately quan-
tified. There were insufficient data (with only 14 “noncured”
events) to allow exploration of multivariable models.
(ii) S. mansoni cure rate by plasma CAA levels and urine
CCA. There was a sustained drop in CAA levels at 24 days. How-
ever, no children at 24 days follow-up achieved negative CAA
levels (10 pg/ml) (Fig. 4). Children that had lower PZQAUC0–24
levels at baseline had higher CAA levels at 24 days follow-up, al-
though this did not reach statistical significance (P  0.071).
Urine CCA negativity was achieved in only 7/58 (12%) children at
follow-up (2 in the 40-mg/kg arm and 5 in the 60-mg/kg arm).
Monte Carlo simulations were performed for three different
dose regimens (40mg/kg, 60mg/kg, and 80mg/kg). The results of
the Monte Carlo simulation are shown in Fig. 5 with individual
cure rates for the different PZQ doses in study patients compared
to simulated patients, adjusting for baseline intensity of infection
and AUC. Only 75% of patients receiving the highest PZQ dose of
80 mg/kg had an estimated cure rate of 85%. Whether dosing
should be further stratified on the basis of other covariates, such as
sex and weight, is possible but requires larger studies.
DISCUSSION
Since 1984, PZQ has been the standard of care for all forms of
schistosomiasis with a recent focus onWHO-approved preventive
chemotherapy campaigns that target school-aged children. De-
spite this, relatively little is known about PZQ drug exposure-
effect relationships which underpin therapeutic efficacy in chil-
dren. Our PK-PD study is the first to quantify the drug exposure-
response relationships using both traditional parasitological (fecal
egg counts per gram of stool [epg]) and novel, more-sensitive
schistosome antigenic assays (CCA and CAA). This is also the first
study of S. mansoni in humans showing differences in enantio-
meric activity on worm reduction. The probability of cure was
strongly associated with high levels of S-PZQ. The R-PZQ form
was eliminated much faster than the S-PZQ form, meaning that
estimates of drug exposure may be less precise and consequently
making it difficult to establish definitive drug exposure-response
relationships. We postulate that there is still the possibility that
TABLE 1 Baseline characteristics of children enrolled in the study
Characteristica
Total no. of children
(n 60)
No. of children or parameter value for children given the following praziquantel dose:
P valueb
40 mg/kg
(n 30)
60 mg/kg
(n 30)
Demography
Bugoigo village 23 11 12 0.99
Walukuba village 37 19 18
Age, yr [mean (range)] 60 6.4 (3–8) 6.3 (3–8) 0.79
3- to 5-year-old (preschool) 17 7 10 0.49
6- to 8-year-old (school-aged) 43 23 20
Females 38 19 19 0.99
Males 22 11 11
Wt, kg [mean (range)] 60 21.8 (15–30) 23.0 (15.1–34) 0.26
Ht, cm [mean (range)] 60 119.4 (101–138) 118.8 (101–139) 0.80
Hematology
Hemoglobin [mean (95% CI)] 59 10.6 (7.3–14.7) 11.3 (10.8–11.8) 0.048
Anemiac 59 23 14 0.062
Parasitic infection
S. mansoni epg stool
[arithmetic mean (CI)]
60 950.4 (324–1,576) 491.0 (249–733) 0.19
Heavy (400 epg) 23 12 11 1.0
Medium (100–399 epg) 17 8 9
Light (1–100 epg) 19 9 10 0.015
No eggs (CCA-positive) 1 1 0
CCA in urine
 9 5 4 0.785
 13 6 7 0.613
 33 16 17 0.99
NA 5 3 2
CAA concn in plasma, pg/ml
[mean (95% CI)]
55 56746 (100–100,839) 43,217 (224–185,672) 0.39
Malaria SD RDT
 32 16 16 P 0.99
 13 7 6
Negative 14 7 7
NA 1 0 1
a Abbreviations: CCA, circulating cathodic antigen; CAA, circulating anodic antigen; 95% CI, 95% confidence interval; NA, not available; RDT, rapid diagnostic text.
b P value is the difference between groups by Fisher exact test or Student’s t test.
c Anemia defined here as hemoglobin level of11.5 g/dl.
Praziquantel PK-PD in Children
July/August 2016 Volume 7 Issue 4 e00227-16 ® mbio.asm.org 3
R-PZQ could be biologically active, but its exposure and activity
are better reflected by the more-abundant S-PZQ form.
In vitro andmurine studies support the antischistosomal activ-
ity of R-PZQ in S. japonicum (5). However, there is still some
controversy regarding the relative potency of PZQ enantiomers
against S. mansoni. Two murine studies with S. mansoni have
demonstrated that R-PZQ has limited activity when assessed by
worm reduction and tegumental damage (32% worm reduction)
(13, 14, 16, 17, 27). A recent study also found R-PZQ to be the
active enantiomer in S. mansoni-infected mice but found no ac-
tivity of its metabolites (15). Clinical correlation, however, is
scant. A PD study in China of 278 patients with S. japonicum
compared a single dose of R-PZQ (20 mg/kg) to racemic PZQ
(40 mg/kg) with posttreatment cure rates of 94.8% and 97.1%,
suggesting that R-PZQ is the active enantiomer (28). Due to such
discrepancies between our study in S. mansoni human subjects
and existing preclinical data, there is an urgent requirement to
better understand species-specific enantiomeric activity of PZQ.
PZQ exhibits considerable interindividual pharmacokinetic
variability. The plasma half-life is short (ca. 2 to 4 h), and there is
almost no parental drug detected in serum 12 to 24 h after dosing.
The majority of PK variability is unexplained. An allometric rela-
tionshipwhere weight affects clearance via a 0.75 scaling exponent
may well be the most appropriate scaling function but would re-
quire PK data from children with a wider range of weights to
investigate this further. Other sources of variation in absorption
likely result from food effects and underlying intestinal disease, as
well as pharmacogenetic determinants of drug clearance. PZQ is
metabolized by CPY3A4, CYP1A2, and CYP2C19, which are
known to exhibit polymorphisms (29) and may be held account-
able, as age-related CYP maturity may explain some of the phar-
macokinetic variability (30). A potential impact of CYP polymor-
phisms in different age and weight groups warrants further
scrutiny.
PZQ binds the tegument of the adult worm, and host-immune
effectors are ultimately responsible for elimination of the parasite
(31). Despite this, there is persistent antischistosomal activity, as
evidenced by a progressive decline in excreted eggs in stool, and in
circulating antigen levels (CAA) in plasma that extends well be-
yond the time that plasma drug concentrations become unde-
tected (Fig. 4). This hysteresis (i.e., apparent disconnect between
drug exposure and various measures of therapeutic effect) may
have several explanations. First, it is possible that PZQ has a pro-
longed mean residence time within the schistosomal tegument or
contiguous host tissues and is able to exert a persistent pharma-
cological effect long after serum drug concentrations are unde-
tected. Second, it is possible that very short exposure to PZQ is
sufficient to initiate changes in the tegument that enable immune
FIG2 Individual PZQ levels by dosing arm. (A) S-PZQ and (B) R-PZQ. The 40-mg/kg dosing arm is indicated in blue, and the 60-mg/kg dosing arm is indicated
in red.
TABLE 2 Pharmacokinetic parameter values derived from the 60 children receiving two different doses of praziquantela
Dose and PZF
enantiomer
Cmax
(g/ml) Tmax (h)
AUC0-
(g · h/ml) t1/2 (h) Tlag
40 mg/kg
S-PZQ 581.3 (677) 3.33 (2.7–3.9) 2.62 (2.8) 2.96 (2.2) 0.07 (0.2)
R-PZQ 131.1 (238) 3.28 (2.6–3.9) 0.50 (0.59) 3.48 (2.3) 0.46 (0.7)
60 mg/kg
S-PZQ 695.56 (810) 3.23 (2.6–3.8) 2.58 (2.5) 3.02 (1.7) 0.13 (0.35)
R-PZQ 144.95 (185) 3.13 (2.6–3.6) 0.43 (0.23) 4.36 (4.7) 0.72 (0.88)
a Values are means, with standard deviations shown in parentheses. The values in parentheses for Tmax show range. Abbreviations: Cmax, maximum concentration of drug in serum;
Tmax, time to maximum concentration of drug in serum; t1/2, half-life; Tlag, lag time (time delay between drug administration and first observed concentration above the lower limit
of quantification in plasma).
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effectors to kill the parasite. The distinction requires further pre-
clinical studies.
Despite the fact that this study was not designed to detect dif-
ferences in therapeutic outcomes with the two treatment regi-
mens, we found a strong relationship between total drugAUC and
parasitological cure while there was no detectable impact of ad-
ministered dose.When CR (i.e., no eggs in stool at follow-up) was
analyzed as a final-outcome measure, higher total PZQ AUCs
were associated with increased cure. Several decades of antimicro-
bial PK-PD research have demonstrated that dose is a notoriously
inaccurate measure of actual drug exposure in clinical settings, as
exemplified by the between-patient variation (Fig. 2). The ability
to resolve drug exposure-effect relationships in this study is al-
most exclusively a function of quantifying drug exposure in terms
of AUC0–24 rather than the reported dose. The extreme PK vari-
ability is the likely explanation for the previous observation that
better response rates are not observed with given higher dosages
(32–34). Overall, higher PZQ dosages than those administered in
this study are required to achieve acceptable cure rates (defined as
a cure rate of 85%) (3). A target AUC should be set for future
studies delivering higher doses than the ones used for this study.
One of the key strengths of our study was inclusion of novel,
more-sensitive antigenic assays (plasma CAA and urine CCA)
used alongside traditional parasitologicalmethods. Although very
poor cure rates were obtainedwhenCCAwas used as ameasure of
cure (12%), a higher proportion of children achieved assay nega-
tivity when given a 60-mg/kg dose (35). Similarly, plasma CAA
levels experienced a high drop at follow-up but at 24 days after
PZQ (mean, 2,582 pg/ml) were still above the thresholds for neg-
ativity (10 pg/ml) (Fig. 4). However, when taken together, a
single PZQ dose in this area where schistosomiasis is highly en-
demic failed to achieve antigenic cure, which is indicative of viable
worms which may simply be due to temporary cessation of egg
excretion by adult females. Facultative egg excretion is a well-
known confounder of parasitological methods and highlights that
future drug development programs should consider the use of
these antigens (CCA andCAA) as bettermeasures of drug efficacy,
over and above fecal egg patency.
Even with the limitation of a small sample size to effectively
detect PD changes, the results of our PK-PD analyses firmly sug-
gest that 40mg/kg is too low a dose. As amatter of clinical urgency,
we suggest that the following studies are needed: (i) further
PK-PD assessment(s) of higher doses in young children, (ii) de-
velopment of an appropriate pharmacodynamic index linking
TABLE 3 Population pharmacokinetic parameter values derived from
the 59 children receiving praziquantela
Pharmacokinetic parameter Mean Median SD CV%
Ka (h1) 14.89 9.88 13.31 89.36
SCL/F (liter/h) 608.02 677.59 320.10 52.65
V/F (liter) 473.97 503.90 244.80 51.65
Kcp (h1) 25.90 22.28 18.89 72.92
Kpc (h1) 33.30 25.71 26.08 78.32
Tlag (h) 1.94 1.67 1.13 58.34
a Abbreviations: Ka, first-order rate constant connecting the gut with the bloodstream;
SCL, clearance of PZQ; Kcp and Kpc, first-order compartmental transfer rate constants
connecting the central and peripheral compartments; V, volume of the central
compartment; F, oral bioavailability of PZQ, which was not estimated in this study;
CV%, coefficient of variation as a percentage.
FIG 3 Observed versus predicted values before (A) and after (B) the Bayesian step.
TABLE 4 Egg reduction rate and cure rate for S. mansoni egg output at
24-day follow-upa
PZQ dose
or P value
ERR (%)
[95% CI]
CR (%)
[95% CI]
40 mg/kg
(n 30)
82 [70–90] 70 [52–83]
60 mg/kg
(n 28)
91 [74–98] 82 [64–92]
P value 0.24b 0.36c
a Abbreviations: ERR, egg reduction rate; CR, cure rate; 95% CI, 95% confidence
interval.
b 95% CI and difference in rates computed using quasibinomial model.
c Exact binomial 95% CI calculated by Fisher’s exact test.
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drug exposure with antiparasitic effect(s), and (iii) clarification of
R-PZQ and S-PZQ activity across all Schistosoma species infec-
tions before monoenantiomeric formulations are introduced.
MATERIALS AND METHODS
Ethics statement. Ethical approval was obtained from the Liverpool
School of Tropical Medicine (application no. 5538/2009) and the Uganda
National Council for Science andMedical Research. Detailed information
sheets were provided to parents and/or guardians. Informed written con-
sent was obtained from the child’s guardian, and verbal assent was also
obtained from children who were able to do so.
Pediatricpopulationandpharmacokineticfield studydesign. InOc-
tober 2012, 60 children from a wider ongoing study cohort were enrolled
from two villages, Bugoigo andWalakuba, along the shores of LakeAlbert,
Uganda. They were initially selected on the basis of the history of S. man-
soni infection as determined during previous surveys (36). All children
had been previously treated with praziquantel (PZQ) (40 mg/kg of body
weight) at least 1 year prior to the current study and had tolerated that
treatment well. The study pediatrician (ALB) performed individual clin-
ical assessments to establish suitability for participation in the study. The
60 subjects were randomized 1:1 to receive a single dose of 40 mg/kg or
60 mg/kg of PZQ. Exclusion criteria were as follows: (i) the child was
acutely unwell as judged by the study pediatrician; and (ii) if the child was
receiving other drug treatments, such as antimalarial agents that could
potentially interact with PZQ. Side effects were recorded using a question-
naire before and 4 h after PZQ administration, and children were moni-
tored for further symptoms for 24 h. These were classified as (i) self-
reported and (ii) observed by the study pediatrician on site. Every child
and parent in the study was also offered treatment for minor medical
conditions. Figure 1 summarizes the sample design and basic methodol-
ogy.
On the day of enrollment, each child arrived at the study site, which
was a rural camp in Bugoigo village in Uganda. A breakfast consisting of
local foods (doughnut, juice, and porridge) was provided before drug
delivery, as food is known to increase PZQ bioavailability (4). PZQ at
either 40 or 60 mg/kg was then administered. Venous blood samples
(2ml)were collected at time zero, 1 h, 2 h, 4 h, 6 h, 12 h, and 24 h into 5-ml
heparinized tubes and centrifuged at 1,000 rpm for 10 min. Plasma was
removed and immediately frozen in liquid nitrogen before being sent to
the United Kingdom and The Netherlands on dry ice for further analysis.
Children stayed on the premises for 24 h and were closely monitored for
delayed drug-related adverse effects.
Parasitological detection and pharmacodynamic endpoints. Two
stool samples (taken on consecutive days) and one urine sample were
collected from every child prior to the start of the study. Double fecal
smears were prepared from each sample applying the thick Kato-Katz
technique for the detection of S. mansoni and other soil-transmitted hel-
minths (37). Mean egg counts per gram of stool (epg) were subsequently
calculated, and three categories were considered for S. mansoni infection:
light (1 to 99 epg), medium (100 to 399 epg), and heavy (400 epg) (6).
FollowingWHOguidelines for the assessment of the drug efficacy of PZQ
against schistosomiasis, standard measures of parasitological cure were
used as primary study endpoints: egg reduction rate (ERR) (the percent-
age decrease in egg count between baseline and follow-up after treatment)
and cure rate (CR) (the percentage of children with no schistosomal eggs
at follow-up after treatment) with an acceptable CR of 85% set by the
WHO (3).
Testing for circulating cathodic antigen (CCA) in urine was per-
TABLE 5 Effects of disease burden, sex, weight, and drug on cure ratea
Factor or parameter Unadjusted ORb P value Adjusted ORc P value AICd
Baseline S. mansoniintensity (by eggs
per gram)
0.99 (0.98–1.00) 0.047 0.99 (0.98–1.00) 0.047
Females 3.18 (0.89–11.3) 0.068 3.65 (0.94–14.2) 0.056
Wt (per kg) 1.28 (1.04–1.57) 0.016 1.27 (1.03–1.57) 0.022
PZQ dose (per mg/kg) 1.03 (0.97–1.10) 0.29 1.02 (0.96–1.09) 0.48 64.8
R-PZQ AUC (log) 1.67 (0.85–3.30) 0.13 1.57 (0.77–3.20) 0.20 63.6
S-PZQ AUC (log) 2.98 (1.40–6.32) 0.004 2.99 (1.36–6.59) 0.005 54.1
Total PZQ AUC (log) 2.31 (1.21–4.40) 0.009 2.24 (1.15–4.37) 0.015 58.0
a Logistic regression unadjusted and adjusted for baseline S. mansoni severity of infection.
b OR, odds ratio. The 95% CI values are shown in parentheses.
c The adjusted odds ratio (OR) was adjusted for baseline severity only. The 95% CI values are shown in parentheses.
d The Akaike information criterion (AIC) values of the fitted models are shown for the various dose measures; lower values indicates a better fit, and differences of 2 to 6 would be
regarded as positive evidence in favor of the selected dose measure. while6 would constitute strong evidence in favor of that measure. The chosen model for simulations based on
the best AIC is shown in boldface type.
FIG 4 Individual CAA levels at baseline and 4 h, 6 h, 24 h, and 24 days post-PZQ for the two dose levels.
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formed using the point-of-care CCA rapid diagnostic test (RapidMedical
Diagnostics, Pretoria, South Africa). The strips were graded upon visual
inspection as trace,,, and (38). Frozen plasma samples from
the subjects were later sent to the Leiden University Medical Center, The
Netherlands, to be tested for the presence of circulating anodic antigen
(CAA) levels by the up-converting phosphor lateral flow (UCP-LF)-based
CAA assay (10). As the CAA levels in the plasma samples were very high,
they were tested in 1/10 and 1/100 dilutions depending on the expected
worm burden of the child. The cutoff for positivity of the assay was
10 pg/ml CAA plasma, corresponding to 10 worm pairs.
Rapid diagnostic tests were also used for the detection ofmalaria (First
Response, Goa, India) and HIV (Determine; Alere, San Diego, CA, USA).
A confirmatory test was available for any HIV tests that were initially
positive (StandardDiagnostics HIV-1/2, Gyeonggi-do, Republic of Ko-
rea).
Quantification and resolution of PZQ racemate and R and S enan-
tiomers. Plasma R-PZQ and S-PZQ concentrations were determined us-
ing a validated liquid chromatography-tandem mass spectrometry (LC/
MS/MS) assay (39). Chromatographic separation was achieved using a
gradient program. The ultrahigh-performance liquid chromatography
(UHPLC) system was interfaced with a triple-quadruple TSQ Quantum
Access mass spectrometer (Thermo Scientific, Hemel Hempstead, United
Kingdom) with a heated electrospray ionization (H-ESI) source. An
E2M28 rotary vacuum pump (Edwards High Vacuum International,
West Sussex, United Kingdom), an NM30LA nitrogen generator (Peak
Scientific, Renfrewshire, United Kingdom), and 99% pure argon gas
(10 liters) (BIP10; Air Products, Liverpool, United Kingdom) were used.
Plasma samples (500 l) containing diazepam as an internal standard
were extracted with a mixture of methyl-tert-butyl ether and dichloro-
methane (2:1, vol/vol), and the resulting dried extract was reconstituted in
mobile phase and injected into the LC/MS/MS. The assay was linear in the
range from 5 to 1,500 ng/ml for both PZQ isomers. The detailed method-
ology is described elsewhere (39).
Pharmacokinetic population analyses. A population methodology
using the program Pmetrics (version 1.2.6) (University of Southern Cal-
ifornia) was used throughout (http://www.lapk.org). Two structural
models were constructed and fitted to the data. In the first model, total
PZQ concentrations (i.e., R-PZQ plus S-PZQ) were assessed. A standard
three-compartment structural pharmacokinetic model was used. The
three compartments were an absorptive compartment (i.e., gut), a central
compartment (bloodstream), and a peripheral compartment. The param-
eters (units shown in brackets or parentheses) describing this model in-
cluded a first-order rate constant connecting the gut with the bloodstream
(Ka [hour1]), two first-order intercompartmental rate constants con-
necting the central and peripheral compartments (Kcp [hour1] and Kpc
[hour1]), first-order clearance from the central compartment (SCL [l/
hour]), volume of the central compartment (Vc [liters]), and an absorp-
tion lag (hours). Oral bioavailability was not estimated. To describe the
population pharmacokinetics of the R and S isoforms, a separate struc-
tural model was developed (data not shown). Potential relationships be-
tween eachmodel parameter and covariates (e.g., weight, age, and gender)
were explored by plotting the Bayesian posterior estimate for the param-
eter against the covariate. Covariates that demonstrated a statistically sig-
nificant relationship with the Bayesian parameter estimates were then
incorporated into the structural model.
The fit of themodel to the data was assessed bymeanweighted error (a
measure of precision), by mean weighted squared error (a measure of
bias), and by visual inspection and coefficient of determination (r2) of the
linear regression of the observed and predicted values both before and
after the Bayesian step.
Pharmacodynamics of PZQ. All data were entered into electronic
format using EpiData (The EpiData Association, Odense, Denmark) and
analyzed using the R statistical package version 3.2.2. (The R Foundation
for Statistical Computing, Vienna, Austria). Cure rate (CR) by egg clear-
ance at 24 days was presented as percent egg negative by two Kato-Katz
thick smears at follow-up with the associated exact binomial 95% confi-
dence interval (95% CI). Multivariable logistic regression models were
used to explore the relationship between CR and demographic and drug
exposure parameters with unadjusted models and models adjusting for
initial disease burden (egg count). A larger model also adjusting for child
weight and sex was considered and gave very similar parameter estimates.
Importantly, however, this model was overfitted given the relatively small
number of events and is therefore not presented here. Since the baseline
intensity prevalence was high, success was also analyzed as egg reduction
rate (ERR) and not solely CR. The ERR was calculated as described else-
where (3). A 95% CI and comparisons between dose groups used a qua-
sibinomial regression model to allow for the overdispersion due to
within-child correlations. Secondary outcomes included antigenic clear-
ance by CCA and CAA levels, and these were explored descriptively.
Monte Carlo simulation. Monte Carlo simulations were performed
using ADAPT 5 (40) and R. The first structural pharmacokinetic model
using total PZQ concentrations was used for the purposes of computa-
tional tractability and to enable future correlation with studies where R
and S enantiomers are not measured. Because of persistent bias when
using the population parameter estimates (with both mean or median
parameter values), we chose not to use these values and the associated
population covariance matrix for the Monte Carlo simulations. Rather,
we used the Bayesian posterior values for each patient, because the indi-
vidual predicted values versus observed values were unbiased (Fig. 3). We
generated 100 simulated patients from each patient’s posterior estimates,
using theirmean parameter estimates and the individual’s covariancema-
trix. Three regimens were considered in these simulations: 40 mg/kg,
60 mg/kg, and 80 mg/kg of PZQ. The AUC was computed for each simu-
lated patient using integration.
A cure model based on a logistic regression fit to the cure rate that
included baseline egg number and total AUCwas used to estimate the cure
probability for each patient. As there was only limited outcome data, it
was not possible to reliably model covariates, such as weight and sex. The
baseline egg count was sampled from the distribution observed in the
treated patients. In order to estimate the errors in the simulated estimates,
1,000 sets of logistic regression parameters were simulated based on draws
from themultivariate normal distribution of the parameter estimates and
their covariance matrix in the logistic regression model. The median and
interquartile ranges of the cure rates for the simulated populations are
presented. Additionally, the proportion of simulated patients achieving a
predicted cure rate of85% was computed.
FIG 5 Model with individual cure rates as outcomes adjusted for infection
intensity and PZQ AUC. The model estimated cure actual patient data (n 
60) for the doses given in the study (40mg/kg and 60mg/kg) are shown in blue.
Data for simulated patients (n  5,000) for three different doses (40 mg/kg,
60 mg/kg, and 80 mg/kg) are shown in black. Error bars on the simulation
results represent the uncertainty (interquartile range) in the simulation due to
parameter variability. The shaded area indicates the WHO target of a 85%
cure rate.
Praziquantel PK-PD in Children
July/August 2016 Volume 7 Issue 4 e00227-16 ® mbio.asm.org 7
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.00227-16/-/DCSupplemental.
Figure S1, JPG file, 0.4 MB.
ACKNOWLEDGMENTS
We express our warm gratitude to the families that agreed to participate
and in particular to the children. We also thank our energetic mobilizers
from Bugoigo and Walukuba in Uganda and the VCD team in Kampala,
Uganda. Thank you to the field team nurses who worked long hours for
this study.
This work was funded by Wellcome Trust grant UK 085440/Z/08/Z.
FUNDING INFORMATION
This work, including the efforts of Amaya L. Bustinduy, was funded by
Wellcome Trust (085440/Z/08/Z).
REFERENCES
1. Doenhoff MJ, Cioli D, Utzinger J. 2008. Praziquantel: mechanisms of
action, resistance and new derivatives for schistosomiasis. Curr Opin In-
fect Dis 21:659–667. http://dx.doi.org/10.1097/QCO.0b013e328318978f
2. Colley DG, Bustinduy AL, Secor WE, King CH. 2014. Human schisto-
somiasis. Lancet 383:2253–2264. http://dx.doi.org/10.1016/S0140
-6736(13)61949-2.
3. World Health Organization. 2013. Assessing the efficacy of anthelmintic
drug against schistosomiasis and soil-transmitted helminthiases. World
Health Organization, Geneva, Switzerland.
4. Mandour ME, el Turabi H, Homeida MM, el Sadig T, Ali HM, Bennett
JL, Leahey WJ, Harron DW. 1990. Pharmacokinetics of praziquantel in
healthy volunteers and patients with schistosomiasis. Trans R Soc Trop
MedHyg 84:389–393. http://dx.doi.org/10.1016/0035-9203(90)90333-A.
5. Olliaro P, Delgado-Romero P, Keiser J. 2014. The little we know about
the pharmacokinetics and pharmacodynamics of praziquantel (racemate
and R-enantiomer). J Antimicrob Chemother 69:863– 870. http://
dx.doi.org/10.1093/jac/dkt491.
6. World Health Organization. 2006. Preventive chemotherapy in human
helminthiasis: coordinated use of anthelminthic drugs in control
interventions: a manual for health professionals and programme manag-
ers. World Health Organization, Geneva, Switzerland.
7. Gönnert R, Andrews P. 1977. Praziquantel, a new board-spectrum anti-
schistosomal agent. Z Parasitenkd 52:129–150. http://dx.doi.org/10.1007/
BF00389899
8. Brindley PJ, Sher A. 1987. The chemotherapeutic effect of praziquantel
against Schistosoma mansoni is dependent on host antibody response. J
Immunol 139:215–220.
9. Coulibaly JT, N’Gbesso YK, Knopp S, N’Guessan NA, Silué KD, van
Dam GJ, N’Goran EK, Utzinger J. 2013. Accuracy of urine circulating
cathodic antigen test for the diagnosis of Schistosoma mansoni in
preschool-aged children before and after treatment. PLoS Negl Trop Dis
7:e2109. http://dx.doi.org/10.1371/journal.pntd.0002109.
10. van Dam GJ, de Dood CJ, Lewis M, Deelder AM, van Lieshout L, Tanke
HJ, van Rooyen LH, Corstjens PL. 2013. A robust dry reagent lateral flow
assay for diagnosis of active schistosomiasis by detection of Schistosoma
circulating anodic antigen. Exp Parasitol 135:274–282. http://dx.doi.org/
10.1016/j.exppara.2013.06.017.
11. Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, Nausch N, Midzi
N,Mduluza T. 2011. Schistosoma haematobium treatment in 1-5 year old
children: safety and efficacy of the antihelminthic drug praziquantel. PLoS
Negl Trop Dis 5:e1143. http://dx.doi.org/10.1371/journal.pntd.0001143.
12. Metwally A, Bennett J, Botros S, Ebeid F, El Attar G-ED. 1995. Impact
of drug dosage and brand on bioavailability and efficacy of praziquantel.
Pharmacol Res 31:53–59. http://dx.doi.org/10.1016/1043-6618(95)80048
-4.
13. Irie Y, Utsunomiya H, Tanaka M, Ohmae H, Nara T, Yasuraoka K.
1989. Schistosoma japonicum and S. mansoni: ultrastructural damage in
the tegument and reproductive organs after treatment with levo- and
dextro-praziquantel. Am J Trop Med Hyg 41:204–211.
14. Tanaka M, Ohmae H, Utsunomiya H, Nara T, Irie Y, Yasuraoka K.
1989. A comparison of the antischistosomal effect of levo- and dextro-
praziquantel on Schistosoma japonicum and S. mansoni in mice. Am J
Trop Med Hyg 41:198–203.
15. Meister I, Ingram-Sieber K, Cowan N, Todd M, Robertson MN, Meli C,
Patra M, Gasser G, Keiser J. 2014. Activity of praziquantel enantiomers
and main metabolites against Schistosoma mansoni. Antimicrob Agents
Chemother 58:5466–5472. http://dx.doi.org/10.1128/AAC.02741-14.
16. Liu YH, Qian MX, Wang XG, Quan YZ, Yan SH, Chen BY, Li JS, Qiu
ZY. 1993. Levo-praziquantel versus praziquantel in experimental and
clinical treatment of schistosomiasis japonica. Chin Med J 106:593–596.
17. Liu YH, Qian MX, Wang XG, Jia J, Wang QN, Jiang YF, Wang RQ, Yan
SH, Chen BY, Li JS. 1986. Comparative efficacy of praziquantel and its
optic isomers in experimental therapy of schistosomiasis japonica in rab-
bits. Chinese Med J 99:935–940.
18. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, Yang QJ, Chen M,
Wang CZ, Zhang ZJ, Liu ZD. 1991. Comparative efficacy of levo-
praziquantel and praziquantel in treatment of schistosomiasis japonica at
a single dose. Chin Med J 104:732–735.
19. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. 2006.
Guidelines on paediatric dosing on the basis of developmental physiology
and pharmacokinetic considerations. Clin Pharmacokinet 45:1077–1097.
http://dx.doi.org/10.2165/00003088-200645110-00003.
20. el Guiniady MA, el Touny MA, Abdel-Bary MA, Abdel-Fatah SA,
Metwally A. 1994. Clinical and pharmacokinetic study of praziquantel in
Egyptian schistosomiasis patients with and without liver cell failure. Am J
Trop Med Hyg 51:809–818.
21. Poole H, Terlouw DJ, Naunje A, Mzembe K, Stanton M, Betson M,
Lalloo DG, Stothard JR. 2014. Schistosomiasis in pre-school-age children
and their mothers in Chikhwawa district, Malawi with notes on charac-
terization of schistosomes and snails. Parasit Vectors 7:153. http://
dx.doi.org/10.1186/1756-3305-7-153.
22. Odogwu SE, Ramamurthy NK, Kabatereine NB, Kazibwe F, Tukahebwa
E, Webster JP, Fenwick A, Stothard JR. 2006. Schistosoma mansoni in
infants (aged  3 years) along the Ugandan shoreline of Lake Victoria.
Ann Trop Med Parasitol 100:315–326. http://dx.doi.org/10.1179/
136485906X105552.
23. Bosompem KM, Bentum IA, Otchere J, Anyan WK, Brown CA, Osada
Y, Takeo S, Kojima S, Ohta N. 2004. Infant schistosomiasis in Ghana: a
survey in an irrigation community. Trop Med Int Health 9:917–922.
http://dx.doi.org/10.1111/j.1365-3156.2004.01282.x.
24. Sousa-Figueiredo JC, Betson M, Atuhaire A, Arinaitwe M, Navaratnam
AM, Kabatereine NB, Bickle Q, Stothard JR. 2012. Performance and
safety of praziquantel for treatment of intestinal schistosomiasis in infants
and preschool children. PLoS Negl Trop Dis 6:e1864. http://dx.doi.org/
10.1371/journal.pntd.0001864.
25. Leopold G, Ungethüm W, Groll E, Diekmann HW, Nowak H, Wegner
DH. 1978. Clinical pharmacology in normal volunteers of praziquantel, a
new drug against schistosomes and cestodes. An example of a complex
study covering both tolerance and pharmacokinetics. Eur J Clin Pharma-
col 14:281–291. http://dx.doi.org/10.1007/BF00560463.
26. World Health Organization. 2011. Report of a meeting to review the
results of studies on the treatment of schistosomiasis in preschool-age
children. World Health Organization, Geneva, Switzerland.
27. Xiao SH, Catto BA. 1989. Comparative in vitro and in vivo activity of
racemic praziquantel and its levorotated isomer on Schistosomamansoni.
J Infect Dis 159:589–592. http://dx.doi.org/10.1093/infdis/159.3.589.
28. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, Yang QJ, Chen M, Jiang
QW, Wang CZ, Zhang SJ. 1991. Comparison of the therapeutic efficacy
and side effects of a single dose of levo-praziquantel with mixed isomer
praziquantel in 278 cases of schistosomiasis japonica. Am J TropMedHyg
45:345–349.
29. Godawska-Matysik A, Kiec´-Kononowicz K. 2006. Biotransformation of
praziquantel by human cytochromeP450 3A4 (CYP 3A4). Acta Pol Pharm
63:381–385.
30. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ,
Zaya MJ. 2003. Developmental expression of the major human hepatic
CYP3A enzymes. J Pharmacol Exp Ther 307:573–582. http://dx.doi.org/
10.1124/jpet.103.054841
31. Becker B, Mehlhorn H, Andrews P, Thomas H, Eckert J. 1980. Light and
electronmicroscopic studies on the effect of praziquantel on Schistosoma
mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda)
in vitro. Z Parasitenkd 63:113–128. http://dx.doi.org/10.1007/
BF00927527.
32. Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J. 2013.
Bustinduy et al.
8 ® mbio.asm.org July/August 2016 Volume 7 Issue 4 e00227-16
Drugs for treating Schistosoma mansoni infection. Cochrane Database
Sy s t Rev 2013 (2 ) :CD000528 . h t tp : / /dx .do i . o rg /10 . 1002 /
14651858.CD000528.pub2.
33. Danso-Appiah A, Utzinger J, Liu J, Olliaro P. 2008. Drugs for treating
urinary schistosomiasis. Cochrane Database Syst Rev 2008(3):CD000053.
http://dx.doi.org/10.1002/14651858.CD000053.pub2.
34. Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M,
Pieri OS, Amarillo ML, Kaatano GM, Diaw M, Domingues AC, Favre
TC, Lapujade O, Alves F, Chitsulo L. 2011. A multicentre randomized
controlled trial of the efficacy and safety of single-dose praziquantel at 40
mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philip-
pines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5:e1165.
http://dx.doi.org/10.1371/journal.pntd.0001165.
35. Sousa-Figueiredo JC, Betson M, Kabatereine NB, Stothard JR. 2013.
The urine circulating cathodic antigen (CCA) dipstick: a valid substitute
for microscopy for mapping and point-of-care diagnosis of intestinal
schistosomiasis. PLoS Negl Trop Dis 7:e2008. http://dx.doi.org/10.1371/
journal.pntd.0002008.
36. Sousa-Figueiredo JC, Pleasant J, Day M, Betson M, Rollinson D, Mon-
tresor A, Kazibwe F, Kabatereine NB, Stothard JR. 2010. Treatment of
intestinal schistosomiasis in Ugandan preschool children: best diagnosis,
treatment efficacy and side-effects, and an extended praziquantel dosing
pole. Int Health 2:103–113. http://dx.doi.org/10.1016/j.inhe.2010.02.003.
37. Katz N, Chaves A, Pellegrino J. 1972. A simple device for quantitative
stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med
Trop Sao Paulo 14:397–400.
38. van Etten L, Folman CC, Eggelte TA, Kremsner PG, Deelder AM. 1994.
Rapid diagnosis of schistosomiasis by antigen detection in urine with a
reagent strip. J Clin Microbiol 32:2404–2406.
39. Lima RM, Ferreira MA, Ponte TM, Marques MP, Takayanagui OM,
Garcia HH, Coelho EB, Bonato PS, Lanchote VL. 2009. Enantioselective
analysis of praziquantel and trans-4-hydroxypraziquantel in human
plasma by chiral LC-MS/MS: application to pharmacokinetics. J Chro-
matogr B Analyt Technol Biomed Life Sci 877:3083–3088. http://
dx.doi.org/10.1016/j.jchromb.2009.07.036.
40. D’Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user’s guide:
pharmacokinetic/pharmacodynamic systems analysis software. Biomedi-
cal Simulations Resource, Los Angeles, CA.
Praziquantel PK-PD in Children
July/August 2016 Volume 7 Issue 4 e00227-16 ® mbio.asm.org 9
